Radiotheranosticsを目指した放射性核種標識化合物開発研究

Development of radiolabeled compounds for radiotheranostics

近年，画一的な治療ではなく，患者個人個人に最適な医療を提供する個別化医療の重要性が叫ばれている。ある治療（治療薬）に対し，それぞれの患者へ効果的かつ安全な治療を行うために，患者がその治療（治療薬）に適しているかを事前に判別する，つまり適合する患者を層別する検査をコンパニオン診断，用いる薬をコンパニオン診断薬と呼び，個別化医療に大きく貢献している^1）。

“Theranostics” is a portmanteau word made by combining “therapeutics” and “diagnostics,” and it must be useful for the personalized medicine concept. Recently, the word, “radiotheranostics,” has also been used. It means theranostics using radioisotopes, which are for imaging and therapy. For radiotheranostics, a diagnostic radiolabeled compound and a corresponding therapeutic radiolabeled compound can be prepared by introducing diagnostic and therapeutic radioisotopes into the same position in the same precursor. These diagnostic and therapeutic radiolabeled compounds are expected to show similar pharmacokinetics, which is vital for radiotheranostics. Diagnostic imaging in radiotheranostics can predict the absorbed radiation dose in each organ for therapy. Thus, the therapeutic and side effects could be calculated. In this manuscript, I describe the development of radiohalogenated compounds targeting sigma-1 receptor and α_Vβ₃ integrin for radiotheranostics.